EQL Pharma AB (publ) provided earnings guidance for the full year 2019. The company estimate that sales for 2018/2019 will increase by more than 30% compared with the corresponding period last year. The company continues to retain its target of growing at least 30% on average per annum over the 5- year period 2016 to 2020/2021, and aims at operating profit to grow at least the same rate as revenue growth. The assumed growth of 30% per annum will be distributed uneven over the five year period.